These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30334211)

  • 1. Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors.
    Dimova D; Bajorath J
    Methods Mol Biol; 2018; 1825():327-337. PubMed ID: 30334211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the scaffold universe of kinase inhibitors.
    Hu Y; Bajorath J
    J Med Chem; 2015 Jan; 58(1):315-32. PubMed ID: 25192260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
    Miljković F; Vogt M; Bajorath J
    J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
    Miljković F; Bajorath J
    J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors.
    Hu H; Bajorath J
    Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target family-directed exploration of scaffolds with different SAR profiles.
    Hu Y; Bajorath J
    J Chem Inf Model; 2011 Dec; 51(12):3138-48. PubMed ID: 22091691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule discrimination map of the antibiotic resistance kinome.
    Shakya T; Stogios PJ; Waglechner N; Evdokimova E; Ejim L; Blanchard JE; McArthur AG; Savchenko A; Wright GD
    Chem Biol; 2011 Dec; 18(12):1591-601. PubMed ID: 22195561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases.
    Dimova D; Bajorath J
    Molecules; 2017 May; 22(5):. PubMed ID: 28467353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Scaffold Hopping.
    Hu Y; Stumpfe D; Bajorath J
    J Med Chem; 2017 Feb; 60(4):1238-1246. PubMed ID: 28001064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural diversity and potency range distribution of scaffolds from compounds active against current pharmaceutical targets.
    Kayastha S; Dimova D; Stumpfe D; Bajorath J
    Future Med Chem; 2015; 7(2):111-22. PubMed ID: 25686001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from molecular scaffold analysis.
    Hu Y; Stumpfe D; Bajorath J
    J Chem Inf Model; 2011 Aug; 51(8):1742-53. PubMed ID: 21755989
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
    Park H; Chi O; Kim J; Hong S
    J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective.
    Hu Y; Kunimoto R; Bajorath J
    Chem Biol Drug Des; 2017 Jun; 89(6):834-845. PubMed ID: 27933727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and Activity Profile Relationships Between Drug Scaffolds.
    Hu Y; Bajorath J
    AAPS J; 2015 May; 17(3):609-19. PubMed ID: 25697829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
    Aronov AM; McClain B; Moody CS; Murcko MA
    J Med Chem; 2008 Mar; 51(5):1214-22. PubMed ID: 18288794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors paradoxically prime kinases.
    Frye SV; Johnson GL
    Nat Chem Biol; 2009 Jul; 5(7):448-9. PubMed ID: 19465930
    [No Abstract]   [Full Text] [Related]  

  • 18. Design of targeted libraries against the human Chk1 kinase using PGVL Hub.
    Peng Z; Hu Q
    Methods Mol Biol; 2011; 685():321-36. PubMed ID: 20981531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
    Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.